Stokes Healthcare Inc., dba Epicur Pharma, Mt. Laurel, NJ
Is Stokes Healthcare Inc., dba Epicur Pharma an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Stokes Healthcare Inc., dba Epicur Pharma in Mt. Laurel, NJ, first registered Jan 30, 2018 and most recently registered Oct 14, 2026. FDA lists its last inspection as May 23, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Response Letter Issued 12/2/2025”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Mt. Laurel, NJ
- Initial registration
- Jan 30, 2018
- Most recent registration
- Oct 14, 2026
- Last inspection
- May 23, 2025
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Response Letter Issued 12/2/2025
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
No entry for this facility was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). FDA may list it under a different name, and the page covers actions from 2019 on.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Stokes Healthcare Inc., Mount Laurel, NJ (FEI number 3002815949), matched to this page by exact name, city and state. It lists 4 inspections: 2 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| May 23, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3002815949 | 1267068 |
| Oct 25, 2023 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3002815949 | 1221039 |
| Oct 9, 2020 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3002815949 | 1131162 |
| Feb 12, 2016 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3002815949 | 957841 |
Form 483s FDA has published for this site
- May 23, 2025: Form 483 to Stokes Healthcare Inc., published Aug 11, 2025. fda.gov
- Oct 25, 2023: Form 483 to Stokes Healthcare Inc., published Mar 22, 2024. fda.gov
- Oct 9, 2020: Form 483 to Stokes Healthcare Inc., published Dec 22, 2020. fda.gov
- Oct 24, 2018: Form 483 to Stokes Healthcare Inc., published Jan 17, 2024. fda.gov
- Apr 6, 2016: Form 483 to Stokes Healthcare Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 9 numbered observations in all, across 2 inspections ending Oct 9, 2020 to May 23, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection May 13, 2025 to May 23, 2025: 5 observations
- Firm on the cover
- Stokes Healthcare Inc. dba Epicur Pharma, 8000 Commerce Pkwy Ste 600, Mount Laurel, NJ 08054-2211
- FEI number
- 3002815949
- Establishment type on the cover
- Producer of Sterile and Non -Sterile Drug Products
- FDA district office on the cover
- 10 Waterview Blvd, 3rd Floor Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
This is a repeat observation.
Specifically,
A. Your firm released several batches of Tacrolimus AQ Ophthalmic Suspension (without labeling them for veterinary use) and other veterinary products intended to be sterile, despite the detection of microbial growth during personnel monitoring (PM) and environmental monitoring (EM) within the ISO 5 production area since October 2023. Your firm has identified positive microbial growth during the EM/PM activities associated with the production of Tacrolimus AQ Ophthalmic Suspension (without labeling them for veterinary use), described as follows:
• MIR-010-2023: Tacrolimus AQ 0.02% Ophthalmic Suspension, Lot# R230600 -2 CFUs of Hansfordia sinuosae (a mold) were identified on the operator's right gloved hand. Date Occurred: 10/6/2023.
• MIR-005-2024: Tacrolimus AQ 0.03% Ophthalmic Suspension, Lot# R240103 -1 CFU of Streptomyces tendae/tritolerans was identified on the left wall within the ISO 5 aseptic processing area. Date Occurred: 2/27/2024. ...
Observation 2
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
This is a repeat observation.
Specifically,
A. The sporicidal agent used to clean the ISO 5 aseptic area did not meet the contact time specified in the cleaning SOP. According to SOP SC-SAN-1010 Cleaning and Maintenance of the Aseptic Manufacturing Area, Revision 2.00, Effective Date: 7/29/2024 <Redacted B4> surface contact time has been established of <Redacted B4> however, camera footage dated 5/12/2025 shows that during the cleaning of the ISO 5 aseptic processing area immediately following the production of Tacrolimus AQ 0.5% (10 mL), Lot <Redacted B4> in Room 706, the operator applied <Redacted B4> at 10:16:59 and wiped it with a mop pre-saturated with <Redacted B4> at 10:21 :41 -resulting in a contact time of less than 5 minutes.
B. The camera footage dated 5/12/2025 shows that the operator did not thoroughly disinfect racks containing wells used to hold caps and tips inside the ISO 5 aseptic processing area prior to use during the production of Tacrolimus AQ 0.5% (10 mL), Lot# <Redacted B4>.
C. ...
Observation 3
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
This is a repeat observation.
Specifically,
The process validation for the Tacrolimus eye drops has not established critical control parameters. <Redacted B4>. During the aseptic filling of Tacrolimus eye drops, <Redacted B4> stir bar inside <Redacted B4> vessel <Redacted B4> stirs the bulk suspension product to maintain uniformity. However, the frrm has not established an acceptable operating range for the stir bar speed. For example, the stir bar speed settings for two different batches of Tacrolimus AQ 1 % Ophthalmic Suspension (Lot# 250197 and Lot# 250227) were <Redacted B4> and <Redacted B4> respectively without an established acceptable range. Since 2024, your frrm has reported 19 out-of-specification (OOS) batches of Tacrolimus eye drops. Of those, 9 batches had confrrmed OOS results and were rejected, but no definitive root causes have been identified during the manufacturing investigation. ...
Observation 4
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
Your stability study failed to test for impurities of Tacrolimus Ophthalmic Suspension including :(6r(4) I individual unspecified impurities and total impurities as specified in the finished product specifications. For example, your firm failed to test for any of these impurities during the K6) (4) !stability study for Tacrolimus AQ 0.02% Ophthalmic Suspension, Lot# R230428 8/22/2023 and th [(6) (4) !stability study for Tacrolimus AQ 0.02% Ophthalmic Suspension, Lot# R230428, initiated on 8/22/2023. Impurities are tested at the time of product release; however, there is no assurance that impurity levels will remain within specification through the product's expiration date. Your firm manufactures approximately LJbatches of Tacrolimus Ophthalmic Suspension pe l(6) (4) lin Room 706.
Observation 5
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that conform to appropriate standards of identity, strength, quality and purity.
This is a repeat observation.
Specifically,
You firm has established an impurity specification for Tacrolimus AQ Ophthalmic Suspension; however, the method for impurity testing -Draft Test Method: Assay of Impurities in Tacrolimus AQ Ophthalmic Suspension by UPLC -has not yet been validated.
Inspection Sep 24, 2020 to Oct 9, 2020: 4 observations
- Firm on the cover
- Stokes Healthcare Inc. dba Epicur Pharma, 8000 Commerce Pkwy Ste 600, Mount Laurel, NJ 08054-2211
- FEI number
- 3002815949
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Deviations from written production and process control procedures are not justified.
Specifically, after the <Redacted B4> were dropped or knocked to the floor following visual inspection. There was no investigation or justification as to why those units were not incubated for the balance of the <Redacted B4> and then inspected for _ turbidity/microbial growth. This media fill, <Redacted B4> , was performed in 6/2020. It was the <Redacted B4> used to validate aseptic processing in cleanroom C704, using your new ophthalmic bottle filling line.
Observation 2
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
Specifically, your firm lacks process control validation data to support the filling of ophthalmic drug products into 8ml and 4ml plastic bottles. Your validation data from 15ml bottles does not directly <Redacted B4>, which operate at <Redacted B4> . Data is missing on line speed conelation to downtime, the number of interventions in the ISO 5 area, and your firm's ability to maintain aseptic conditions throughout the manufacturing process.
on line speed conelation to downtime, the number of interventions in the ISO 5 area, and your film's ability to maintain aseptic conditions throughout the manufacturing process.
Observation 3
Procedures describing the handling of all written and oral complaints regarding a drug product are not established and followed.
Specifically, product complaints received between 3/10/2020 and 9/23/2020 were not entered into your Client Notice of Event Report and evaluated for product quality issues. At least seven (7) examples (complaints 20-007 to 20-0013) were noted.
Observation 4
Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
Specifically, your firm has not established bulk hold times in your master batch records or written procedures. The existing practice of <Redacted B4> ophthalmic liquids and injectable drug product <Redacted B4> does not establish a formal process control parameter. This deficiency could result in fwther processing and/or the release of a drug product which was not processed within validated parameters.
Linked 483s whose text is not shown
- Oct 25, 2023: FDA document 177221: its numbered observations could not be read reliably from the PDF text.
- Oct 24, 2018: FDA document 114353: the FEI number and firm name on its cover do not match this page by the rule.
- Apr 6, 2016: FDA document 96110: its numbered observations could not be read reliably from the PDF text.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Stokes Healthcare Inc., dba Epicur Pharma). That is not a finding beyond this index’s search.
The Stokes Healthcare Inc., dba Epicur Pharma pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.